Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Research Lab for High-Value Generics Goes Live: Kobayashi Kako
July 23, 2014
- Terumo US Unit Opens New Plant in Vietnam
July 23, 2014
- Tatsumi Kagaku Adjusts Supply of Nu-lotan Generic
July 22, 2014
- Disclosure of Payments from Drug Makers to Doctors Delayed
July 22, 2014
- Chugai Obtains Marketing Rights for Antiemetic NEPA in the UK, Ireland from Helsinn Group
July 22, 2014
- Ethical Drug Sales Down 6.5% in May: Crecon Report
July 18, 2014
- Novartis, Maruho Form Sales Tie-Up for Psoriasis Agent
July 18, 2014
- Carna Shooting for 1st Licensing Deal on Kinase Inhibitor in 2014
July 18, 2014
- Ono to Target Cancers with Unmet Medical Needs: President
July 18, 2014
- AnGes MG Initiates Development of Next Generation Collategene
July 18, 2014
- OncoTherapy Appoints Prof. Nakamura as Special Science Advisor
July 18, 2014
- Merck Serono Japan Hopes to Boost Erbitux Share by Narrowing Down CRC Patients: President
July 17, 2014
- Chugai, Zeltia Sign Commercialization Agreement for Plitidepsin in Europe
July 17, 2014
- AZ Begins Nexium Clinical Study for Pediatric Use in Japan
July 17, 2014
- Ono President Professes High Hopes for Newly Approved Anticancer Drug Opdivo
July 16, 2014
- Antiepileptic Treatment Aptiom Approved in Canada: Sumitomo Dainippon
July 16, 2014
- Astellas Files Irribow for Diarrhea-Predominant Irritable Bowel Syndrome in Females
July 16, 2014
- Ex-Astellas Chair Sounds Alarm over Oncology-Focused Businesses, Says Govt Finances Will Be Insufficient
July 15, 2014
- Kyowa Kirin’s UK Subsidiary Acquires Archimedes
July 15, 2014
- Otsuka Files NDA for Abilify Successor Drug Brexpiprazole in US
July 15, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…